You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Baxter
Moodys
Merck
Medtronic

Last Updated: May 14, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207934

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 207934 describes EVEROLIMUS, which is a drug marketed by Mylan, Biocon Pharma, Breckenridge, Hikma, Par Pharm, and Teva Pharms Usa, and is included in eight NDAs. It is available from six suppliers. Additional details are available on the EVEROLIMUS profile page.

The generic ingredient in EVEROLIMUS is everolimus. There are twelve drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the everolimus profile page.
Summary for 207934
Tradename:EVEROLIMUS
Applicant:Par Pharm
Ingredient:everolimus
Patents:0
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 207934
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EVEROLIMUS everolimus TABLET;ORAL 207934 ANDA Par Pharmaceutical, Inc. 49884-119 49884-119-91 28 BLISTER PACK in 1 CARTON (49884-119-91) > 1 TABLET in 1 BLISTER PACK (49884-119-52)
EVEROLIMUS everolimus TABLET;ORAL 207934 ANDA Par Pharmaceutical, Inc. 49884-125 49884-125-91 28 BLISTER PACK in 1 CARTON (49884-125-91) > 1 TABLET in 1 BLISTER PACK (49884-125-52)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2.5MG
Approval Date:Dec 9, 2019TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:Dec 9, 2019TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength7.5MG
Approval Date:Dec 9, 2019TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
AstraZeneca
McKinsey
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.